Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330197 · ClinicalTrials.gov registry record · Phase 1
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
A Phase 1 study, sponsored by Alaunos Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03330197 is a Phase 1 study that was terminated before completion, run by Alaunos Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT03330197, a Phase 1 study, was terminated before completion, sponsored by Alaunos Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. The main purpose of this study is to evaluate the safety and tolerability of a single tumor injection of Ad-RTS-hIL-12 given with oral veledimex in the pediatric population.
Interventions
- BIOLOGICAL Ad-RTS-hIL-12
- DRUG Oral Veledimex - Arm 1 (Pediatric Brain Tumor)
- DRUG Oral Veledimex - Arm 2 (DIPG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-09-26 |
| Est. Completion | 2021-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03330197
The ClinicalTrials.gov registry entry for NCT03330197 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ad-RTS-hIL-12 is the first listed.
NCT03330197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03330197 about?
NCT03330197 is a clinical study titled "A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG". This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to...
What is the current status of trial NCT03330197?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-09-26. Estimated completion is 2021-09-10.
What interventions are being tested in trial NCT03330197?
The interventions under investigation include: Ad-RTS-hIL-12 (BIOLOGICAL), Oral Veledimex - Arm 1 (Pediatric Brain Tumor) (DRUG), Oral Veledimex - Arm 2 (DIPG) (DRUG).
Who is sponsoring clinical trial NCT03330197?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.